{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:22:03Z","timestamp":1787642523312,"version":"build-2736575974"},"reference-count":33,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Int AIDS Soc."],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The impact of pre\u2010exposure prophylaxis (PrEP) on the US HIV\u20101 epidemic has not been fully maximized, potentially due to challenges in uptake, coverage, adherence and consistent use. Following the FDA (Food and Drug Adminstration) approval of twice\u2010yearly lenacapavir, epidemiological projections are needed to understand the potential role of lenacapavir in overcoming PrEP barriers. The objective of this analysis was to estimate the impact of lenacapavir on HIV\u20101 incidence in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used a static cohort model representing the US population aged 15 or older to predict the number of HIV\u20101 cases averted between 2026 and 2030 under different lenacapavir uptake scenarios (S1\u2013S5) versus projected status quo 2025 PrEP use with no lenacapavir (S0). In S0 and S3, we assumed 2025 levels of PrEP use (652K total PrEP users with no lenacapavir use) for 2026\u20132030. In all other scenarios, we assumed PrEP use increases to 1.1 million PrEP users with 0%\u2212100% using lenacapavir. Oral and injectable PrEP effectiveness were based on clinical trials adjusted by percent days covered in real\u2010world use. Oral PrEP use was assumed to be zero among people who inject drugs in all scenarios.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In S1, moderate lenacapavir uptake (37% of PrEP users by 2030) averted 13,700 (95% credible interval: 10,800\u201318,300) new HIV\u20101 cases, an 8% (6%\u201310%) reduction in cumulative cases between 2026 and 2030 relative to S0. In S2, more rapid lenacapavir uptake (85% of PrEP users by 2030) averted 23,800 (19,100\u201333,700) cases. Switching all PrEP users to lenacapavir averted 22,400 (12,200\u201347,200) and 37,400 (26,800\u201361,200) cases without (S3) and with (S4) an increase in PrEP use, respectively. In S5, 9400 (4600\u201311,500) cases were averted if PrEP use increased but lenacapavir was not introduced. This analysis was limited as only reductions in primary acquisitions were considered in the static cohort model and the model did not account for potential future demographic or behavioural shifts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Twice\u2010yearly lenacapavir may impact the US HIV\u20101 epidemic by improving adherence and increasing the duration of protection relative to oral PrEP, leading to more consistent protection over time and reducing HIV\u20101 incidence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jia2.70188","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:48:44Z","timestamp":1786369724000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Modelling the 5\u2010Year Impact of Twice\u2010Yearly Injectable Lenacapavir for HIV Pre\u2010Exposure Prophylaxis in the United States"],"prefix":"10.1002","volume":"29","author":[{"given":"Mia","family":"Moore","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Disease Division Fred Hutchinson Cancer Center  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serin","family":"Lee","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division Fred Hutchinson Cancer Center  Seattle Washington USA"},{"name":"Department of Industrial and Management Engineering Incheon National University  Incheon South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Matrajt","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division Fred Hutchinson Cancer Center  Seattle Washington USA"},{"name":"Department of Applied Mathematics University of Washington  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Stansfield","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division Fred Hutchinson Cancer Center  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Tao","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Yang","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Mezzio","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Jarrett","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JeanPierre Coaquira","family":"Castro","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woodie","family":"Zachry","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dobromir","family":"Dimitrov","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division Fred Hutchinson Cancer Center  Seattle Washington USA"},{"name":"Department of Applied Mathematics University of Washington  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"[Available from: accessed October 2025]U.S. Food and Drug Administration Truvada Package Insert Gilead Sciences Inc. (2004)https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021752s035lbl.pdf."},{"key":"e_1_2_12_3_1","unstructured":"[Available from: accessed October 2025]U.S. Food and Drug Administration Descovy Package Insert Gilead Sciences Inc. (2015)https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208215s012lbl.pdf."},{"key":"e_1_2_12_4_1","unstructured":"[Available from:U.S. Food and Drug Administration Apretude Package Insert Gilead Sciences Inc. (2021)https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215499s000lbl.pdfaccessed October 2025]."},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411858"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407001"},{"key":"e_1_2_12_7_1","unstructured":"[Available from:U.S. Food and Drug Administration Yeztugo Package Insert Gilead Sciences Inc. (2025)https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/220020s000lbl.pdfaccessed October 2025]."},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(25)00036-0"},{"key":"e_1_2_12_9_1","unstructured":"[Available from:CDC National Center for HIV Viral Hepatitis STD and Tuberculosis Prevention(2024)https:\/\/www.cdc.gov\/nchhstp\/index.htmlaccessed July 2025]."},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01295-0"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-025-00584-0"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26496"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00030-3"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100738"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26459"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00538-4"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101016"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-083837"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0309811"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003029"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa552"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26109"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0312369"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.2196\/publichealth.5365"},{"issue":"37","key":"e_1_2_12_25_1","first-page":"757","article-title":"Estimated Percentages and Characteristics of Men Who Have Sex With Men and Use Injection Drugs\u2013United States, 1999\u20132011","volume":"62","author":"CDC","year":"2013","journal-title":"MMWR Morbidity and Mortality Weekly Report"},{"key":"e_1_2_12_26_1","unstructured":"United States Census Bureau Census Bureau Data. [Available from: data.census.gov\/. Data available athttps:\/\/www2.census.gov\/programs\u2010surveys\/popest\/datasets\/2020\u20102022\/counties\/asrh\/cc\u2010est2022\u2010all.csv also insurance rate datasets ACSDT1Y2023 C27001 and ACSDT5Y2023 C27001A C27001B\u2010I C27002 and C27003 (accessed February 2025)]."},{"key":"e_1_2_12_27_1","unstructured":"[Available from:CDC HIV Surveillance Supplemental Report: Estimated HIV Incidence and Prevalence in the United States 2018\u20132022(2024)https:\/\/stacks.cdc.gov\/view\/cdc\/156513accessed July 2025]."},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2023.00808"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.6390"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.focus.2024.100311"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(24)00239-X"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.31341"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.21346"},{"key":"e_1_2_12_34_1","unstructured":"Available from:ClinicalTrials.gov Study of Lenacapavir and Emtricitabine\/\u200bTenofovir Disoproxil Fumarate (F\/\u200bTDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103) (PURPOSE 4)(2026)https:\/\/clinicaltrials.gov\/study\/NCT06101342."}],"container-title":["Journal of the International AIDS Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.70188","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jia2.70188","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.70188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:58:45Z","timestamp":1787641125000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.70188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/jia2.70188"],"URL":"https:\/\/doi.org\/10.1002\/jia2.70188","archive":["Portico"],"relation":{},"ISSN":["1758-2652","1758-2652"],"issn-type":[{"value":"1758-2652","type":"print"},{"value":"1758-2652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2026-02-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70188"}}